文献速递慢阻肺肺栓塞与肺血管病

磷酸二酯酶-5抑制剂与慢阻肺相关肺动脉高压患者生存改善的关联

Association of Phosphodiesterase-5 Inhibitor Treatment With Improved Survival in Pulmonary Hypertension Associated With COPD in the Pulmonary Vascular Research Institute GoDeep Meta-Registry.
PubMed 文献 · Chest · 2024-09-07

基于GoDeep国际多中心注册数据库,纳入836例经右心导管确诊的慢阻肺合并肺动脉高压患者,中位年龄66岁,51%为男性。50%患者接受PDE5i治疗,多因素Cox回归显示PDE5i与全因死亡风险降低相关(HR 0.65),landmark分析结果一致(HR 0.83)。

要点

  • 慢阻肺合并肺动脉高压患者5年无移植生存率仅42%,预后差。
  • 肺血管阻力是死亡的主要预测因素,而FEV1不是。
  • PDE5i治疗与死亡风险显著降低相关,各亚组结果稳健。

核心结论

  • 在慢阻肺合并肺动脉高压患者中,PDE5i治疗与显著降低的死亡风险相关,且在各模型中结果一致。

研究设计与样本

  • 研究基于Pulmonary Vascular Research Institute GoDeep meta-registry,纳入836例经右心导管确诊的慢阻肺合并肺动脉高压患者,采用Cox回归、亚组分析和landmark方法分析PDE5i与无移植生存的关联。

主要发现

  • 患者中位年龄66岁,FEV1占预计值51%,mPAP 35 mm Hg,PVR 5 WU,心脏指数2.5 L/min/m2,多为WHO功能分级III级。
  • 5年无移植生存率为42%,显著低于第1组肺动脉高压。
  • 多变量Cox模型显示PVR而非FEV1是结局的主要预测因素。
  • 亚组分析(中重度肺动脉高压、不同合并症、需补充氧气)及未观测混杂因素评估均再现PDE5i效应。

关键数值与推荐

  • 严重肺动脉高压定义为PVR>5 Wood units(WU)。
  • PDE5i与死亡风险降低相关:全队列HR 0.65(IQR 0.57-0.75),landmark分析HR 0.83(IQR 0.74-0.94)。

临床怎么用

  • 对慢阻肺合并肺动脉高压患者,尤其是PVR升高者,可考虑PDE5i治疗以改善无移植生存,但需结合合并症和氧疗需求个体化评估。

局限性

  • 研究为meta-registry回顾性分析,存在未观测混杂因素,PDE5i效应虽经多种模型验证但仍需前瞻性研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with COPD frequently demonstrate pulmonary hypertension (PH). Severe PH in patients with COPD, identified by pulmonary vascular resistance (PVR) of > 5 Wood units (WU), is closely linked to impaired transplant-free survival. The impact of PH-targeting pharmacotherapy in this context remains unclear. RESEARCH QUESTION: Is PH-targeted therapy associated with improved transplant-free survival in patients with COPD and PH? STUDY DESIGN AND METHODS: This study included Pulmonary Vascular Research Institute GoDeep meta-registry patients with COPD and PH and available right heart catheterization at diagnosis. We investigated PH-targeted therapy prevalence and its association with transplant-free survival using diverse statistical methods, including Cox regression and subgroup analyses based on PH severity, comorbidities, and pulmonary function test results. Immortal time bias was addressed through a landmark approach. RESULTS: As of December 2023, the GoDeep meta-registry included 26,981 patients (28% in PH group 1, 13% in PH group 2, 12% in PH group 3, 10% in PH group 4, 2% in PH group 5, 26% undefined, and 9% control participants). Of these, 836 patients had a diagnosis of COPD with PH and were included in this analysis, with median age of 66 years (interquartile range [IQR], 59-73 years), FEV1 of 51% predicted (IQR, 34%-69% predicted), mPAP of 35 mm Hg (IQR, 28-44 mm Hg), PVR of 5 WU (IQR, 4-8 WU), cardiac index of 2.5 L/min/m2 (IQR, 2.0-2.9 L/min/m2), and mostly World Health Organization functional class III were included. Five-year transplant-free survival was 42%, significantly worse than in group 1 PH. A multivariable Cox proportional hazards model identified PVR, but not FEV1, as a major predictor of outcome. Four hundred eighteen patients (50%) received phosphodiesterase-5 inhibitor (PDE5i) therapy, which was associated with significantly reduced mortality: hazard ratio of 0.65 (IQR, 0.57-0.75) for the entire cohort of patients with COPD and PH and of 0.83 (IQR, 0.74-0.94) when performing landmark analysis. This PDE5i effect was reproduced robustly when performing subgroup analyses for patients with moderate to severe PH, various comorbidities, and supplemental oxygen requirement and when assessing the impact of unobserved confounders. INTERPRETATION: Patients with COPD and PH exhibit poor transplant-free survival, with PVR being a predictor of mortality. In this meta-registry, PDE5i therapy was associated with a significant reduction in mortality across all tested models.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Tello K, Yogeswaran A, Majeed RW, et al. Association of Phosphodiesterase-5 Inhibitor Treatment With Improved Survival in Pulmonary Hypertension Associated With COPD in the Pulmonary Vascular Research Institute GoDeep Meta-Registry. Chest. 2024. PMID: 39182575. doi:10.1016/j.chest.2024.08.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。